Latest filing published 07 Mar 2025 for AMOEBA, €2,515. Read the official filing
Based on 6 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Jean-Luc SOUCHE, listed as board member, appears in our data through filings on Amoeba shares, published by AMF. Over a trading history stretching from 26 July 2023 to 6 March 2025, the count stands at 9 filings.
Both buying and selling appear: 6 purchases worth €13k, against 3 sales worth €4,685. The net balance comes to €7,952 on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2025: 2 purchases and no sales on the market.
The median purchase comes to €2,273. On 3 out of 6 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Looking at 6 purchases old enough to measure, the stock rose over the following 90 days in 100% of cases; the median change was +35.0%. These figures describe past trades and do not predict future prices.
The newest entry dates from 7 March 2025: an open-market purchase of €2,515, in Amoeba. The median gap between a trade and its publication by AMF is 4 days. For comparison, MAR article 19 gives managers three business days to notify a trade. This summary is built from AMF disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
9 of 9 declarations